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C hronic graft-versus-host disease (cGVHD) is an important late complication after allogeneic 
hematopoietic stem cell transplantation (HSCT).  It is 
estimated that half of long-term survivors of allogeneic 
HSCT will develop cGVHD,  and it is the cause of 
death in up to 80  of patients with severe cGVHD 
[1].  Chronic GVHD is also associated with an 
impaired quality of life [2].  In addition to donor-re-
cipient disparity of human leukocyte antigen (HLA),  
the use of unrelated donors (increased minor HLA 
antigen disparity),  donor-recipient sex disparity and 
increasing donor age [3],  peripheral blood stem cell 
transplantation (PBSCT) increase the relative risk of 
cGVHD by 40-50  rather than bone marrow trans-
plantation (BMT) [4].  With the dramatic increase of 
unrelated PBSCT recently in Japan,  cGVHD will 
remain a major problem aﬀecting long-term survivors 
after allogeneic HSCT.
　 Chronic GVHD involve a variety of organs,  com-
monly including skin,  liver,  eyes,  oral mucosa/minor 
salivary glands,  lungs,  kidneys,  soft tissues and joints,  
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Chronic graft versus host disease (cGVHD) remains a major problem for long survivors after alloge-
neic hematopoietic stem cell transplantation (HSCT).  Currently,  corticosteroid therapy is eﬀective for 
cGVHD as the ﬁrst line therapy.  However,  prolonged therapy with corticosteroids causes various 
severe adverse events.  To develop the new therapeutic strategy of cGVHD,  we have launched a mul-
ticenter phase I/IIa clinical trial of low dose subcutaneous interleukin-2 (IL-2) for treatment of steroid 
refractory cGVHD,  which is constituted of 2 sequential phases (induction phase and maitanance phase).  
This study will provide the new therapeutic option for patients with refractory cGVHD after alloge-
neic HSCT.
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and show various clinical manifestations.  The patho-
physiology of cGVHD is not well understood.  The 
increased risk of cGVHD after major or minor HLA 
mismatched HSCT suggests that the expansion of 
cytotoxic T cells against these mismatched antigens is 
a main mechanism of cGVHD.  Corticosteroids are the 
ﬁrst line therapy for cGVHD.  Currently,  however,  
there is no standard second line therapy for cGVHD,  
and therapy typically requires prolonged administra-
tion of corticosteroid combined with other immuno-
suppressive agents such as calcineurin inhibitors.  
Despite combined immunosuppressive therapy,  only 
54  of patients were successfully weaned of cortico-
steroids at 5 years [5].  Prolonged therapy with cor-
ticosteroids often causes various severe adverse 
events.  It is clear that new approach in the therapy of 
refractory cGVHD is urgently required.
　 Regulatory T cells (Tregs) are a distinct CD4＋ T 
cell subset of mature T cells,  which have an essential 
role in the control of normal immune tolerance [6,7].  
After the development in thymus,  mature Tregs con-
stitute 1-5  of the circulating CD4＋ T cell popula-
tion.  Tregs can suppress eﬀector CD4＋ and CD8＋ 
T cells by various mechanisms (directly; cell contact 
dependent inhibition of antigen presenting cell func-
tion,  indirectly; production of inhibitory cytokines 
such as Interleukin-10 and Transforming growth fac-
tor-β) [8].  In murine allogeneic BMT model,  infused 
Tregs suppressed allo-reactive eﬀector T cells and 
acute GVHD [9,10].  In murine solid tumor model,  
Tregs did not suppress anti-tumor eﬀect in vivo 
[11,12].  In humans,  patients with cGVHD have rel-
ative deﬁciency of Tregs [13,14].  These results 
suggest that Tregs can induce selective immune sup-
pression and play an indispensable function of immune 
tolerance after allogeneic HSCT.
　 Interleukin-2 (IL-2) is a cytokine critical for the 
development,  expansion and peripheral activity of 
Tregs [15,16].  The constitutive expression of high- 
aﬃnity IL-2 receptors enables Tregs to selective 
respond and activation to low dose IL-2 [17].  The 
deﬁciency of Tregs in cGVHD patients was restored 
by the exogeneous administration of low dose IL-2 
[18,19].  In these clinical trials,  daily low dose IL-2 
therapy for 8-12 weeks led to selective Treg expan-
sion and improvement of clinical GVHD symptoms in 
more than 50  of patients [18,19].  Low dose IL-2 
has also impacted on Treg homeostasis (increase of 
proliferation,  generation from thymus and anti-apop-
tosis activity) [20].  These results indicate that low 
dose IL-2 therapy can reversibly correct the abnormal 
Treg homeostasis as new immune approach after allo-
geneic HSCT.  
　 Here,  in order to develop more safe and durable 
prolonged low dose IL-2 therapy,  we have conducted 
the new strategy of low dose IL-2 therapy which is 
composed of 2 sequential phases (induction phase and 
maintenance phase).  In this phase I/IIa study,  we will 
study the safety and eﬃcacy of 2 sequential phases low 
dose IL-2 therapy in patients with steroid refractory 
cGVHD.
Treatment Methods
　 This study is a single arm,  non-randomized,  
open-label phase I/IIa trial of recomibinant human 
IL-2 (UMIN registration number: 000022253).  IL-2 
(Teceleukin) was supplied by Shionogi,  which did not 
have any input into the manuscript content or the deci-
sion to submit the manuscript for publication.  This is 
a multi-center trial involving ten hamatological institu-
tions: Okayama University Hospital,  Sapporo Medical 
University Hospital,  Tokyo Metropolitan Cancer and 
Infectious Diseases Center Komagome Hospital,  
National Cancer Center Hospital,  Chiba University 
Hospital,  Nagoya University Hospital,  Kansai Medical 
University Hospital,  Minami-Okayama Medical Center,  
Ehime Prefectural Central Hospital and Kyushu 
University Hospital.  The co-ordination of the study 
will be carried out by the Okayama University 
Hospital,  department of Hematology and Oncology.  
Written informed consent must be obtained by an 
investigator from the patient before any screening or 
inclusion procedure.  This study was conducted in 
compliance with the principles of the Declaration of 
Helsinki,  and the protocol was approved by the insti-
tutional review boards of each of the participating 
hospital (The local Ethical Committee Board approval 
number: 270201).
　 Treatment is composed of two sequential phases:  
the induction phase and the maintanance phase.  In the 
induction phase,  IL-2 is subcutaneously administrated 
once per day for 4 weeks.  In the sequential main-
tanance phase,  IL-2 is subcutaneously administrated 
three times per week for following 8 weeks.  Patients 
with safe toxicity proﬁle and clinical beneﬁt could 
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continue to receive subcutaneous IL-2 for the addi-
tional 36 weeks.  There are three dose levels of IL-2 
in the Phase I part of this study: level A at 3×104,  
level B at 1×105 and level C at 3×105 international 
units/m2/day.  Level A is the starting dose,  and ini-
tially 3 patients are administered.  The schema of 
dose escalation is shown in Fig.  1.  The maxium toler-
ated dose (MTD) of IL-2 is determined in the Phase I 
part and the MTD is administrated in the Phase IIa 
part of this study.  The MTD is deﬁned as the dose 
with dose limiting toxicity (DLT) in one or less patient 
received IL-2.  DLT is deﬁned by the following crite-
ria.  Severity of toxicity is assessed according to the 
Common Terminology Criteria for Adverse Events 
v4.0 (CTCAE v4.0).  (1) Grade 4 anaphylaxis: Life 
threatening anaphylaxis secondary to IL-2,  (2) Severe 
thrombotic microangiopathy (Grade 3: Blood and 
Marrow Transplant Clinical Trials Network Criteria),  
(3) Grade 4 non-hematologic toxicity directly related 
to IL-2 by week 4 of IL-2 treatment,  (4) Grade 4 
hematologic toxicity,  not related to 
malignant disease relapse,  infection 
or other etiologies (absolute neutro-
phil count: ANC＜500/mm3 or plate-
let count＜25,000/mm3),  (5) Grade 3 
non-hematologic toxicity with intoler-
ance judged by attending physicians,  
(6) Grade 2 non-hematologic toxic-
ity 3 days with intolerance judged 
by attending physicians,  (7) Delay to 
receive IL-2 8 days in the induc-
tion phase,  (8) Progression of cGVHD 
(Clinical signs of progression of 
cGVHD while on IL-2,  that require 
the addition of a new immunosup-
pressive medication or the increase 
in the corticosteroid dose).  The dose 
determining commitie reviews the 
interim analysis after the dose of 
each level and then provide decisions 
regarding the choice of dose to 
administer to subsequent partici-
pants.  The dose determining com-
mitie will also review all safety data 
accumulated in the trial at each meet-
ing.  Up to 18 participants with 
refractory cGVHD will be enrolled in 
the trial to determine the MTD.
Eligibility Criteria
　 The inclusion and exclusion crite-
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Fig. 1　 Scheme of dose escalation.  #/# indicates the 
number of patients with dose-limiting toxicity (DLT)/total 
number of patients.  MTD,  maxium tolerated dose.  The MTD 
is deﬁned as the dose with DLT in one or less of at least 6 
patient received each level of IL-2.
ria are as listed in Table 1.
Endpoints and Statistical Consideration
　 The primary end point in the phase I part is the 
detection of the MTD of a 4 week course of IL-2 in 
patients with cGVHD.  The primary end point in the 
phase IIa part is the proportion of 12-week Failure 
Free Survival (FFS) in all eligible patients,  including 
the patients in the phase I part,  as the index of the 
eﬃcacy of IL-2.  FFS is deﬁned from the date of the 
ﬁrst IL-2 administration to the date of the non-relapse 
death,  the relapse of disease and the change of sys-
temic therapy for cGVHD.  Kaplan-Meier method will 
be used to calculate the probability of FFS.  The 
second endpoints are the safety proﬁles based on 
CTCAE in 12-week and long-term ( 48 weeks) IL-2 
administration,  the clinical response evaluated by 
National Institutes of Health consensus criteria and 
substantial reduction in the steroid dose,  and the 
immune response in terms of increase in Tregs.  
Safety and tolerability assessments include clinical 
history,  physical examination,  body temperature,  
blood pressure,  heart rate,  12-lead electrocardio-
gram,  chest X-ray,  clinical laboratory tests,  plumonary 
function test and adverse event recording.  The subset 
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Table 1　 Patient eligibility
Inclusion criteria
 1) Recipients of allogeneic HSCT with myeloablative or nonmyeloablative conditioning regimens
 2) Patients must be at least 180 days from the allogeneic HSCT
 3) Patients with steroid refractory chronic GVHD,  deﬁned as persistent symptom of cGVHD despite the use of prednisoe at 1.0 mg/
kg/day for at least 2 weeks,  0.5 mg/kg/day for at least 4 weeks or 1.0 mg/kg every other day for at least 4 weeks
 4) Patients with stable dose of corticosteroids for 2 weeks prior to enrollment
 5) No addition or subtraction of other immunosuppressive medications for 4 weeks prior to enrollment
 6) Patients with adequate organ function (ANC＞1,000/mm3,  Platelet count＞50,000/mm3,  Absolute lymphocyte count＞400/mm3,  
Aspartate aminotransferase＜2x upper limit of normal (ULN),  Total bilirubin＜2.0 mg/dl,  Serum creatinine＜2x ULN
 7) Patient age 18 years
 8) Patients with reproductive potential must agree to use a appropriate method of birth control during treatment and for six months after 
completion of treatmen
 9) Written informed consent
Exclusion criteria
 1) Ongoing prednisone requirement 1 mg/kg/day
 2) Exposure to any immunosuppressive medication in the 2 weeks prior to enrollment (Tumor Necrosis Factor inhibitor,  Bortezomib,  
Rituximab or Imatinib)
 3) Exposure to any investigational therapy in the 4 weeks prior to enrollment (e.g.,  extracorporeal photopheresis,  ultraviolet or 
Tamibarotene)
 4) Post-transplant exposure to any immunomodulatory drug within 180 days prior to enrollment (Antithymocyte globulin,  Alemtuzumab,  
OKT3,  Mogamulizumab,  Basiliximab,  Denileukin diﬃtox,  Brentuximab vedotin,  Nivolumab,  Pembrolizmab,  Atezolizumab,  
Avelumab,  Ipilimumab,  Abatacept or Natalizumab)
 5) Active malignant disease relapse
 6) Active,  uncontrolled infection
 7) Active infection with hepatitis B virus or hepatitis C virus
 8) Life expectancy＜3 months
 9) Pregnancy or lactation
 10) Patients without ability to comply IL-2 treatment regimen
 11) Uncontrolled cardiac angina or symptomatic congestive heart failure (New York Heart Association: Class III or IV)
 12) Organ transplant recipient
 13) Recipients received allogeneic HSCT from HLA-mismatched ( 2/6) donor,  except for umbilical cord blood transplant 
 14) Unstable cardiac angina,  cardiac infarction,  deep vein thrombosis or cerebral infarction (CTCAE Grade 3)
 15) Anticoagulant therapy
 16) History of severe thrombotic microangiopathy
 17) Hematological malignancy expressing CD25 (IL-2 receptor)
 18) History of allergy to biological products (e.g. vaccine)
 19) Patients judged inappropriate for this study by attending physicians
of lymphocyte (T cells,  B cells and NK cells) are mea-
sured by ﬂow cytometry following IL-2 treatment to 
assess the immune response.
Discussion
　 We have planned this phase I/IIa trial,  which will 
reveal the MTD of low dose IL-2 and whether the 
strategy of low dose IL-2 therapy which is composed 
of two distinct phases can maintain tolerance eﬀects in 
selected patients with steroid refractory cGVHD.  We 
consider it a crucial point in the treatment protocol 
that intermittent administration of IL-2 after consec-
utive administration are design to develop more safe 
and durable prolonged low dose IL-2 therapy.  We 
hope this study will provide novel ﬁndings those open 
the door to a new therapeutic strategy for steroid 
refractory cGVHD.
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